Fucoidan Alleviates Renal Fibrosis in Diabetic Kidney Disease via Inhibition of NLRP3 Inflammasome-Mediated Podocyte Pyroptosis

• Main Authors: Mei-Zi Wang (Author), Jie Wang (Author), Dong-Wei Cao (Author), Yue Tu (Author), Bu-Hui Liu (Author), Can-Can Yuan (Author), Huan Li (Author), Qi-Jun Fang (Author), Jia-Xin Chen (Author), Yan Fu (Author), Bing-Ying Wan (Author), Zi-Yue Wan (Author), Yi-Gang Wan (Author), Guo-Wen Wu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Fucoidan (FPS) has been widely used to treat renal fibrosis (RF) in patients with diabetic kidney disease (DKD); however, the precise therapeutic mechanisms remain unclear. Recently, research focusing on inflammation-derived podocyte pyroptosis in DKD has attracted increasing attention....